Comparing two ways to give terlipressin for variceal bleeding in ACLF
Part of Digestive system clinical trials.
This trial compares giving terlipressin as a continuous infusion versus as a bolus for people with ACLF who have bleeding from varices in the esophagus. The goal is to see which method works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult aged 18 or older.
- You have been diagnosed with ACLF (a serious liver condition that develops quickly).
- You currently have active bleeding from varices (enlarged veins) in your esophagus.
- You do not have a history of heart disease, stroke, asthma, or seizures.
- You are not pregnant and have not had a previous bleed come back.
- You do not have liver cancer or a bleed from varices in your stomach.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a continuous infusion of terlipressin (a medicine that helps raise blood pressure and protect kidneys) to standard norepinephrine treatment improves kidney recovery in people with acute-on-chronic liver failure, acute kidney injury, and septic shock.
This trial tests whether using a slightly different target on a blood-clotting test (ROTEM) can reduce the need for blood transfusions in people with liver disease who need a procedure. If you have cirrhosis or ACLF with severe clotting problems, this study may help your doctors decide how much blood product to give you before the procedure.
This trial tests whether a treatment called therapeutic plasma exchange (a process that filters your blood) can help improve the function of other organs in people with severe liver failure. It aims to see if this treatment leads to better outcomes and to find markers that predict who will benefit.
This study compares two strong antibiotics—ceftazidime-avibactam and a high dose of meropenem given over a longer infusion—in patients with advanced liver disease who develop a hospital-acquired infection. The goal is to see which works better and is safer.
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
This trial compares two approaches to prevent first-time bleeding from enlarged veins in the food pipe (varices) in people with liver cancer and cirrhosis. One group receives a daily pill (carvedilol), and the other receives the pill plus a procedure (endoscopic banding) to tie off the veins.
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.